{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:16:27Z","timestamp":1789690587064,"version":"4.0.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T00:00:00Z","timestamp":1710979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T00:00:00Z","timestamp":1710979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-024-04834-4","type":"journal-article","created":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T12:02:07Z","timestamp":1711022527000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Treatment patterns and prognosis in patients with Bacillus Calmette\u2013Gu\u00e9rin-exposed high-risk non-muscle invasive bladder cancer: a real-world data analysis"],"prefix":"10.1007","volume":"42","author":[{"given":"Nobutaka","family":"Nishimura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9503-7356","authenticated-orcid":false,"given":"Makito","family":"Miyake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Iida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuki","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryotaro","family":"Tomida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyuki","family":"Numakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Inokuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Yoneyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eijiro","family":"Okajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shugo","family":"Yajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Terada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikiya","family":"Taoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naotaka","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyohide","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,21]]},"reference":[{"key":"4834_CR1","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2022","unstructured":"Babjuk M, Burger M, Capoun O et al (2022) European Association of Urology Guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol 81:75\u201394","journal-title":"Eur Urol"},{"key":"4834_CR2","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/iju.14281","volume":"27","author":"H Matsumoto","year":"2020","unstructured":"Matsumoto H, Shiraishi K, Azuma H et al (2020) Clinical Practice Guidelines for Bladder Cancer 2019 update by the Japanese Urological Association: summary of the revision. Int J Urol 27:702\u2013709","journal-title":"Int J Urol"},{"key":"4834_CR3","doi-asserted-by":"publisher","first-page":"866","DOI":"10.6004\/jnccn.2022.0041","volume":"20","author":"TW Flaig","year":"2022","unstructured":"Flaig TW, Spiess PE, Abern M et al (2022) NCCN Guidelines\u00ae Insights: bladder cancer, Version 2.2022. J Natl Compr Cancer Netw. 20:866\u2013878","journal-title":"J Natl Compr Cancer Netw."},{"key":"4834_CR4","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","volume":"196","author":"SS Chang","year":"2016","unstructured":"Chang SS, Boorjian SA, Chou R (2016) Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO Guideline. J Urol 196:1021\u20131029","journal-title":"J Urol"},{"key":"4834_CR5","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","volume":"34","author":"AM Kamat","year":"2016","unstructured":"Kamat AM, Sylvester RJ, Bohle A et al (2016) Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group. J Clin Oncol 34:1935\u20131944","journal-title":"J Clin Oncol"},{"key":"4834_CR6","unstructured":"US Food and Drug Administration. BCG-unresponsive nonmuscle invasive bladder cancer: developing drugs and biologics for treatment guidance for industry. Silver Spring, MD: FDA; 2018. https:\/\/www.fda.gov\/media\/101468\/download."},{"key":"4834_CR7","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","volume":"22","author":"SA Boorjian","year":"2021","unstructured":"Boorjian SA, Alemozaffar M, Konety BR et al (2021) Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol 22:107\u2013117","journal-title":"Lancet Oncol"},{"key":"4834_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2023.01.013","author":"BA Inman","year":"2023","unstructured":"Inman BA, Hahn NM, Stratton K et al (2023) A phase 1b\/2 study of atezolizumab with or without Bacille Calmette\u2013Gu\u00e9rin in patients with high-risk non-muscle-invasive bladder cancer. Eur Urol Oncol. https:\/\/doi.org\/10.1016\/j.euo.2023.01.013","journal-title":"Eur Urol Oncol."},{"key":"4834_CR9","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","volume":"22","author":"AV Balar","year":"2021","unstructured":"Balar AV, Kamat AM, Kulkarni GS et al (2021) Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol 22:919\u2013930","journal-title":"Lancet Oncol"},{"issue":"491","key":"4834_CR10","first-page":"e1","volume":"40","author":"C Yong","year":"2022","unstructured":"Yong C, Mott SL, Steinberg RL et al (2022) A longitudinal single center analysis of T1HG bladder cancer: an 18 year experience. Urol Oncol 40(491):e1-491.e9","journal-title":"Urol Oncol"},{"key":"4834_CR11","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.eururo.2023.01.017","volume":"83","author":"NM Hahn","year":"2023","unstructured":"Hahn NM, O\u2019Donnell MA, Efstathiou JA et al (2023) A phase 1 trial of durvalumab in combination with Bacillus Calmette\u2013Guerin (BCG) or external beam radiation therapy in patients with BCG-unresponsive non-muscle-invasive bladder cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study. Eur Urol 83:486\u2013494","journal-title":"Eur Urol"},{"key":"4834_CR12","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.eururo.2021.12.005","volume":"82","author":"M Roumigui\u00e9","year":"2022","unstructured":"Roumigui\u00e9 M, Kamat AM, Bivalacqua TJ et al (2022) International bladder cancer group consensus statement on clinical trial design for patients with Bacillus Calmette\u2013Gu\u00e9rin-exposed high-risk non-muscle-invasive bladder cancer. Eur Urol 82:34\u201346","journal-title":"Eur Urol"},{"key":"4834_CR13","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","volume":"163","author":"DL Lamm","year":"2000","unstructured":"Lamm DL, Blumenstein BA, Crissman JD et al (2000) Maintenance bacillus Calmette\u2013Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163:1124\u20131129","journal-title":"J Urol"},{"key":"4834_CR14","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u2019EZR\u2019 for medical statistics. Bone Marrow Transplant 48:452\u2013458","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"4834_CR15","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.urology.2007.09.050","volume":"71","author":"BL Gallagher","year":"2008","unstructured":"Gallagher BL, Joudi FN, Maym\u00ed JL, O\u2019Donnell MA (2008) Impact of previous bacille Calmette\u2013Gu\u00e9rin failure pattern on subsequent response to bacille Calmette\u2013Gu\u00e9rin plus interferon intravesical therapy. Urology 71(2):297\u2013301","journal-title":"Urology"},{"issue":"5","key":"4834_CR16","first-page":"e9","volume":"38","author":"MJ Daniels","year":"2020","unstructured":"Daniels MJ, Barry E, Schoenberg M et al (2020) Contemporary oncologic outcomes of second induction course BCG in patients with nonmuscle invasive bladder cancer. Urol Oncol 38(5):e9-5.e16","journal-title":"Urol Oncol"},{"key":"4834_CR17","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s12885-021-07966-7","volume":"21","author":"M Miyake","year":"2021","unstructured":"Miyake M, Iida K, Nishimura N et al (2021) Non-maintenance intravesical Bacillus Calmette\u2013Gu\u00e9rin induction therapy with eight doses in patients with high- or highest-risk non-muscle invasive bladder cancer: a retrospective non-randomized comparative study. BMC Cancer 21:266","journal-title":"BMC Cancer"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-024-04834-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-024-04834-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-024-04834-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T21:24:23Z","timestamp":1735853063000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-024-04834-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,21]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4834"],"URL":"https:\/\/doi.org\/10.1007\/s00345-024-04834-4","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,21]]},"assertion":[{"value":"3 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the Institutional Review Board of Nara Medical University (reference number: 2217) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The opt-out method was used to obtain consent from participants through the use of posters and\/or websites.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"185"}}